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Cerebral  Cavernous  Malformation  (CCM)  is  a vascular  disease  of  proven  genetic  origin, which  may  arise
sporadically  or  is inherited  as  an  autosomal  dominant  condition  with  incomplete  penetrance  and  highly
variable  expressivity.  CCM  lesions  exhibit  a range  of  different  phenotypes,  including  wide  inter-individual
differences  in lesion  number,  size,  and  susceptibility  to  intracerebral  hemorrhage  (ICH).  Lesions  may
remain  asymptomatic  or result  in  pathological  conditions  of  various  type  and  severity  at any  age, with
symptoms  ranging  from  recurrent  headaches  to severe  neurological  deﬁcits,  seizures,  and  stroke.  To  date
there  are  no  direct  therapeutic  approaches  for CCM  disease  besides  the  surgical  removal  of  accessible
lesions.  Novel  pharmacological  strategies  are  particularly  needed  to limit  disease  progression  and  severity
and prevent  de  novo formation  of CCM lesions  in  susceptible  individuals.
Useful insights  into  innovative  approaches  for  CCM  disease  prevention  and  treatment  are  emerging
from  a growing  understanding  of  the  biological  functions  of the  three  known  CCM  proteins,  CCM1/KRIT1,
CCM2  and  CCM3/PDCD10.  In particular,  accumulating  evidence  indicates  that these  proteins  play major
roles  in  distinct  signaling  pathways,  including  those  involved  in  cellular  responses  to oxidative  stress,
inﬂammation  and angiogenesis,  pointing  to pathophysiological  mechanisms  whereby  the function  of
CCM  proteins  may  be  relevant  in preventing  vascular  dysfunctions  triggered  by  these  events.  Indeed,
emerging  ﬁndings  demonstrate  that  the pleiotropic  roles  of CCM  proteins  reﬂect  their  critical  capacity  to
modulate the  ﬁne-tuned  crosstalk  between  redox  signaling  and  autophagy  that  govern  cell homeostasis
and  stress  responses,  providing  a novel  mechanistic  scenario  that  reconciles  both  the  multiple  signaling
pathways  linked  to  CCM  proteins  and  the distinct  therapeutic  approaches  proposed  so  far.  In  addition,
recent  studies  in  CCM  patient  cohorts  suggest  that  genetic  susceptibility  factors  related  to differences
in  vascular  sensitivity  to oxidative  stress  and  inﬂammation  contribute  to inter-individual  differences  in
CCM disease  susceptibility  and  severity.This review  discusses  recent  progress  into  the  understanding  of  the  molecular  basis  and  mechanisms  of
CCM  disease  pathogenesis,  with  speciﬁc  emphasis  on  the  potential  contribution  of altered  cell responses
to oxidative  stress  and  inﬂammatory  events  occurring  locally  in  the  microvascular  environment,  and
consequent  implications  for the  development  of  novel,  safe,  and  effective  preventive  and  therapeutic
strategies.
© 2016  The  Author(s).  Publi
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1. Introduction
Cerebral Cavernous Malformations (CCM), also known as
cavernous angioma or cavernoma, are vascular malformations con-
sisting of closely clustered, abnormally dilated and leaky capillary
channels (caverns) lined by a thin endothelial layer (Batra et al.,
2009; Fontanella, 2015; Gault et al., 2004; Rigamonti, 2011). Lesions
are devoid of normal vessel structural components, such as peri-
cytes and astrocyte foot processes, but are surrounded by a thick,
segmentally layered basal membrane (Clatterbuck et al., 2001).
CCM lesions can occur anywhere in the body, but usually produce
serious signs and symptoms only when they occur in brain and
 under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. MRI  appearance of a Cerebral Cavernous Malformation.
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gxial T2 FSE MRI  of a CCM lesion in an affected patient (image courtesy of Dr. Maria
onsuelo Valentini, “Città della Salute e della Scienza” University Hospital of Torino,
taly).
pinal cord, where they account for 5–15% of all vascular malfor-
ations. Retinal, skin, and liver lesions have also been occasionally
eported in association with brain lesions. Within the brain, CCM
an occur as single or multiple lesions (even hundreds), ranging in
ize from a few millimeters to a few centimeters. Lesions can remain
linically silent for a lifetime, or unpredictably give rise to vari-
us clinical symptoms including headaches, neurological deﬁcits,
eizures, stroke, and intracerebral hemorrhage (ICH) (Batra et al.,
009; Fontanella, 2015; Gault et al., 2004; Rigamonti, 2011).
Diagnosis is commonly made by magnetic resonance imaging
MRI) (Fig. 1), although detection is far more likely via gradient-
cho (GRE) or susceptibility-weighted imaging (SWI), which can
nmask small lesions (Campbell et al., 2010; Cooper et al., 2008; de
ouza et al., 2008). Because of a large series of MRI  and autopsy stud-
es, CCM disease has been recognized as a common clinical entity.
ndeed, the prevalence of CCM lesions in the general population
as been estimated to be about 0.3%–0.5%, accounting for approxi-
ately 24 million people worldwide (Batra et al., 2009; Fontanella,
015; Rigamonti, 2011). Nevertheless, knowledge and risk aware-
ess of this disease is generally poor. Moreover, diagnosis is mainly
ossible only when lesions become symptomatic, because the
ajority of CCM lesions apparently remain clinically and biolog-
cally quiescent during most of the host’s lifetime. Indeed, despite
he high prevalence of CCM lesions, approximately only 30% of
ffected people will eventually develop clinical symptoms, which
re extremely variable and may  have a major impact on the qual-
ty of life. The initial presentation of symptoms may  occur at any
ge without sex predominance, although the typical age of onset
s between the second and ﬁfth decades of life (Batra et al., 2009;
ontanella, 2015; Rigamonti, 2011).
CCM is a disease of proven genetic origin (OMIM 116860) that
ay  arise sporadically or is inherited as an autosomal dominant
ondition with incomplete penetrance and variable expressivity
Cavalcanti et al., 2012; Riant et al., 2010). The sporadic form (sCCM)
ccounts for up to 80% of cases, whereas the familial form (fCCM)
ccounts for at least 20% of cases. Genetic studies have so far
dentiﬁed three genes whose mutation causes CCM: KRIT1 (CCM1),
GC4607 (CCM2)  and PDCD10 (CCM3), which account for about
0%, 20% and 10% of the fCCM cases, respectively. The remaining
0% of cases have been attributed either to other so far undetected
enetic alterations in the three known CCM genes or to mutationsiochemistry & Cell Biology 81 (2016) 254–270 255
of a fourth as yet unidentiﬁed CCM gene (Choquet et al., 2015;
Riant et al., 2010). A genetic founder mutation in KRIT1 (Q455X, also
known as the common Hispanic mutation) is found in descendants
of Hispanic-Americans who  settled in the southwestern United
States and northern Mexico states (Polymeropoulos et al., 1997),
and today accounts for the largest population of fCCM worldwide,
with thousands of affected patients and varying degrees of clinical
severity (Choquet et al., 2014a; Sahoo et al., 1999). Recent studies
of this population have facilitated the identiﬁcation of genetic and
environmental risk factors associated with CCM disease progres-
sion and severity (Choquet et al., 2014a, b, 2016). Like the common
Hispanic mutation, most of the hundreds of distinct mutations
identiﬁed so far in the three known CCM genes are loss-of-function
mutations (Choquet et al., 2015; Riant et al., 2010). Notably, while
the sporadic form of the illness typically presents as a solitary
lesion, the familial form is characterized by the presence of multiple
CCM lesions, which are associated with cutaneous and retinal vas-
cular lesions in 9% and 5% of fCCM cases, respectively. Conversely,
in contrast to fCCM cases, CCM lesions of sCCM cases are frequently
associated with a developmental venous anomaly (DVA), suggest-
ing the possibility of a different developmental mechanism (Meng
et al., 2014; Petersen et al., 2010).
Despite the apparent higher disease severity in fCCM cases, up
to 70% of mutation carriers remain asymptomatic or minimally
symptomatic throughout life. Moreover, a large variability of dis-
ease severity is observed even among family members of similar
ages carrying the same disease-associated genetic defect, includ-
ing wide inter-individual differences in lesion number, size and
susceptibility to ICH, suggesting that additional factors other than
the disease-causing mutation can contribute to CCM disease patho-
genesis (Trapani and Retta, 2015). Although signiﬁcant advances
have been made toward understanding the natural history and
molecular basis of CCM disease (Batra et al., 2009; Fischer et al.,
2013; Fontanella, 2015; Gault et al., 2004; Marchi et al., 2016b;
Rigamonti, 2011), the clinical behavior in individual patients,
including the development of numerous and large lesions, and the
risk of serious complications such as ICH, remains highly unpre-
dictable (Fontanella and Bacigaluppi, 2015). Furthermore, despite
the long-held dogma that CCM lesions are congenital and the clear
evidence that they may  remain clinically and biologically quies-
cent during the host’s lifetime, there are several instances where
their de novo formation, increase in size, and recurrent phases of
hemorrhage over time has been carefully documented by serial
MRI  scans (Acciarri et al., 2009; Jung et al., 2003; Yadla et al.,
2010). A complete understanding of pathogenic mechanisms and
risk factors associated with onset, clinical progression, and sever-
ity of CCM disease remains therefore a major clinical and research
challenge. This challenge must be met  in order to identify new
pharmacological therapies and prognostic factors, thus ultimately
providing better options for disease treatment and prevention.
Indeed, while medications are available to treat some clinical symp-
toms caused by CCM lesions, including headaches and seizures,
to date there are no direct therapeutic approaches for CCM dis-
ease, besides the surgical removal of accessible lesions in patients
with intractable seizures or recurrent hemorrhage (Fontanella and
Bacigaluppi, 2015). In particular, novel pharmacological strategies
are specially needed for treating patients with severe symptomatic
disease due to inoperable or multiple lesions, as well as for pre-
venting de novo formation of CCM lesions and disease progression
in susceptible individuals. In addition, the identiﬁcation of speciﬁc
risk and susceptibility factors for developing the most severe forms
of CCM disease and appropriate biomarkers of disease progression
and severity is required to allow accurate risk assessment and more
speciﬁc diagnosis, thus providing useful insights into predictors of
disease outcome, early therapeutic interventions, and surveillance
of treatment effects.
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Table  1
Molecular pathways altered by loss-of-function of CCM proteins, and potential pharmacological approaches for the prevention or treatment of CCM disease proposed so far.
Molecular Pathway KRIT1 CCM2 PDCD10 Pharmacological approaches Experimental Articles
Adherens junctions Yes Yes n.d. Antioxidant compounds and
autophagy inducers (Tempol, Vitamin
D3); inhibitors of the TGF- and
-catenin pathways (Sulindac sulﬁde
and its analogs)
Glading et al., 2007; Glading and Ginsberg, 2010;
Lampugnani et al., 2010; Corr et al., 2012; Gibson et al.,
2015; Bravi et al., 2015, 2016
Autophagy Yes Yes Yes Autophagy inducers (Rapamycin,
Torin1)
Marchi et al., 2015
-catenin* Yes No Yes Inhibitors of the -catenin pathway
(Sulindac sulﬁde and its analogs)
Glading and Ginsberg, 2010; Boulday et al., 2011; Bravi
et al., 2015
1 integrin adhesion Yes Yes n.d. Zhang et al., 2001; Zawistowski et al., 2002; Faurobert
et al., 2013; Liu et al., 2013; Macek Jilkova et al., 2014;
Renz et al., 2015
JNK/c-Jun Yes n.d. n.d. Antioxidant compounds
(N-acetylcysteine)
Goitre et al., 2014
FoxO1 Yes Yes n.d. Antioxidant compounds
(N-acetylcysteine, Avenanthramide)
Goitre et al., 2010; Moglia et al., 2015; Gibson et al.,
2015
Kruppel-like factors
(KLF2/4)
Yes n.d. n.d. Cuttano et al., 2016; Renz et al., 2015; Zhou et al.,
2015; Zhou et al., 2016
MEKK3 Yes Yes Yes Uhlik et al., 2003; Fisher et al., 2015; Zhou et al., 2015;
Cullere et al., 2015; Zhou et al., 2016
Notch/ERK Yes n.d. Yes Multikinase inhibitors (Sorafenib) Schulz et al., 2015; Wustehube et al., 2010; You et al.,
2013
RhoA/ROCK Yes Yes Yes Inhibitors of Rho signaling and
multi-target compounds (Statins,
Fasudil, Tempol, vitamin D3)
Crose et al., 2009; Whitehead et al., 2009; Borikova
et al., 2010; Stockton et al., 2010; Zheng et al., 2010;
Chan et al., 2011; McDonald et al., 2012; Richardson
et al., 2013; Gibson et al., 2015; Zhou et al., 2016
ROS** Yes Yes Yes Antioxidant compounds and
autophagy inducers (N-acetylcysteine,
Avenanthramide, Tempol, Vitamin D3,
Torin 1, Pt NPs)
Goitre et al., 2010, 2014; Fidalgo et al., 2012; Moglia
et al., 2015; Gibson et al., 2015; Marchi et al., 2015;
Moglianetti et al., 2016
STRIPAK*** No No Yes Zheng et al., 2010; Chan et al., 2011; Fidalgo et al.,
2012; Voss et al., 2007; Zhang et al., 2013b
TGF/BMP and EndMT Yes n.d. Yes Inhibitors of the TGF- pathway
(Sulindac sulﬁde and its analogs)
Maddaluno et al., 2013; Bravi et al., 2015, 2016
VEGF Yes n.d. Yes VEGFR inhibitors (Semaxanib) He et al., 2010; Zhu et al., 2010; DiStefano et al., 2014
n.d.—not determined.
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a* -catenin transcriptional activity.
** ROS production and redox signaling.
*** STRIPAK (striatin-interacting phosphatase and kinase) complex-related pathwa
In recent years, great progress has been made toward under-
tanding the molecular basis and mechanisms of CCM disease
athogenesis, revealing a stunning complexity (Marchi et al.,
016b). In contrast, little progress has been made in understanding
ow this complexity could be fully embraced and integrated into
 unique model of interconnected mechanisms that may  combine
o inﬂuence the onset, progression, and severity of CCM disease.
ndeed, advances from distinct in vitro and in vivo studies support
n important role for either oxidative stress, inﬂammation or angio-
enesis in the pathogenesis of CCM disease (Corr et al., 2012; Goitre
t al., 2010, 2014; Shi et al., 2016; Wustehube et al., 2010; Zhu
t al., 2010). Consistently, accumulating evidence demonstrates
hat loss-of-function of CCM proteins has pleiotropic effects poten-
ially related to the ability of these proteins to regulate multiple
olecules and molecular mechanisms involved in angiogenesis,
ascular homeostasis, and cell responses to oxidative stress and
nﬂammation, including those that mediate or modulate cell-cell
nd cell-matrix adhesions, cytoskeleton dynamics, redox signaling,
nd gene expression (Marchi et al., 2016b). However, despite their
ell-established interconnected nature, the potential causes and
echanisms of CCM disease are usually considered separately and
ttributed to speciﬁc functions of CCM proteins.This review intends to bring together current knowledge and
ongoing investigations that highlight the pleiotropic effects of CCM
proteins in the pathophysiology of CCM disease. This will include
their multifaceted roles in adaptive cell responses to oxidative
stress, inﬂammation, and angiogenesis— emphasizing the intricate
interplay between these processes. We  will also examine to what
extent this comprehensive understanding appears promising for
the development of novel preventive and therapeutic strategies,
and the identiﬁcation of useful diagnostic and prognostic biomark-
ers.
2. Current knowledge of the molecular basis and
mechanisms of CCM disease pathogenesis
Comprehensive analysis of the three known CCM genes in muta-
tion carriers has indicated that CCM protein functions need to be
severely impaired for pathogenesis (Riant et al., 2010). Consis-
tently, molecular and immunohistochemical analysis of surgical
samples have suggested that CCM lesion genesis requires complete
loss-of-function of a CCM gene through a two-hit molecular mech-
anism (Akers et al., 2009; Gault et al., 2004; McDonald et al., 2011;
Pagenstecher et al., 2009). However, the second somatic mutation
was detected only in a small percentage of cells (Akers et al., 2009).
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oreover, both clinical reports and experiments in animal models
ave raised the possibility that the ‘second hit’ may  not be lim-
ted to genetic disruptions but could also take the form of recurrent
xposure of the particularly sensitive brain vasculature to local cel-
ular stresses (Jung et al., 2003; Leblanc et al., 2009; Whitehead
t al., 2009). Accordingly, it has been reported that CCM3 mouse
utants only develop lesions in conjunction with severe astrocy-
osis at the lesion site, suggesting that injury of astrocytes may  play
 role in lesion formation (Louvi et al., 2011), a notion consistent
ith clinical reports of CCM developing or expanding after physical
rauma, injury, or radiation (Cutsforth-Gregory et al., 2015; Louvi
t al., 2011). Furthermore and importantly, the development of
CM lesions induced by endothelial-speciﬁc conditional knockout
f CCM genes in neonatal mice is highly restricted, both spatially
nd temporally, despite the pan-endothelial deletion of CCM genes
Boulday et al., 2011; Chan et al., 2011; Gibson et al., 2015; Zhou
t al., 2016). This clearly demonstrates that the homozygous loss
f CCM genes is not fully sufﬁcient to cause CCM lesion formation
nd disease progression, and suggests the necessary contribution
f additional triggers occurring locally, which may  include micro-
nvironmental stress factors or brain injuries. Consistently, clinical
eatures of CCM disease, including lesion number and size, rate of
ecurrent bleeding, age-of-onset, and severity of symptoms, vary
reatly even between family members carrying the same causative
ene mutation, raising the possibility that the level of risk for CCM
isease onset and progression is determined by a combination of
ultiple factors. These may  include disease-associated mutations,
istinct microenvironmental stressors, and interindividual vari-
bility in stress response (Choquet et al., 2016; Trapani and Retta,
015).
To date, numerous studies have demonstrated that CCM pro-
eins are implicated in the regulation of major cell structures and
ignaling mechanisms involved in fundamental physiological func-
ions, as well as in cell responses to various physio-pathological
tressors (Marchi et al., 2016b) (Table 1). However, no study has so
ar undertaken the difﬁcult work of organizing and prioritizing the
dentiﬁed signaling pathways in the context of the natural history of
CM, thus each pathway presently stands as a separate entity, inde-
endent of the others. Among others, it has been shown that CCM
roteins regulate cadherin-mediated cell-cell junctions (Glading
t al., 2007; Glading and Ginsberg, 2010; Lampugnani et al., 2010),
ntegrin-mediated cell-matrix adhesion (Faurobert et al., 2013; Liu
t al., 2013; Macek Jilkova et al., 2014), and Rho GTPase-regulated
ytoskeleton dynamics (Borikova et al., 2010; Crose et al., 2009;
ichardson et al., 2013; Stockton et al., 2010; Whitehead et al.,
009; Zheng et al., 2010).
The initial identiﬁcation of KRIT1 as a Rap1 GTPase effector
hat interacts with the endothelial adherens junction (AJ) com-
lex involving VE-cadherin, p120-catenin and -catenin, and the
iscovery that loss of this protein promotes the weakening of VE-
adherin-mediated cell-cell adhesion and consequent dysfunction
f the endothelial barrier, led to the original hypothesis that loss
f blood-brain barrier (BBB) function contributes to the formation
f CCM (Glading et al., 2007; Glading and Ginsberg, 2010). Though
he interface for this interaction remains unclear, the binding of
he small GTPase Rap1 to the FERM domain of KRIT1 is thought
o promote the interaction of KRIT1 with the AJ (Glading et al.,
007). Conversely, Liu et al. demonstrated that a mutant KRIT1 that
annot bind Rap1 loses its ability to localize to AJ and remains cyto-
lasmic (Liu et al., 2011b). Besides Rap1, KRIT1 has other direct
inding partners, including CCM2 (Zawistowski et al., 2005) and
CAP1 (Zawistowski et al., 2002; Zhang et al., 2001), and also indi-
ectly binds to CCM3/PDCD10 (Voss et al., 2007). However, while
here is evidence that CCM2 is also localized to endothelial cell-cell
ontacts (Whitehead et al., 2009), this has not been demonstrated
or other KRIT1 interacting proteins.iochemistry & Cell Biology 81 (2016) 254–270 257
More recently, it has been established that CCM proteins
may  also regulate integrin-based focal adhesions, which con-
nect endothelial cells to the underlying extracellular matrix, and
integrin-mediated signaling (Faurobert et al., 2013; Liu et al., 2013;
Macek Jilkova et al., 2014; Renz et al., 2015). Speciﬁcally, there is
evidence that CCM proteins limit 1 integrin-dependent endothe-
lial cell adhesion, contractility, and ﬁbronectin remodeling by
stabilizing ICAP1, an inhibitor of 1 integrin (Faurobert et al., 2013;
Liu et al., 2013), and may  control endothelial 1 integrin-dependent
mechanotransduction in response to shear stress (Macek Jilkova
et al., 2014; Renz et al., 2015).
Besides the direct regulation of cadherin- and integrin-mediated
cell adhesion, a recurring theme dominating the recent scientiﬁc
literature is the causal link between loss-of-function of CCM pro-
teins and hyperactivation of the small GTPase RhoA and its effector
Rho kinase (ROCK). RhoA activation increases cellular contractil-
ity and destabilizes endothelial AJs, thereby reducing endothelial
barrier function and increasing vascular permeability (Borikova
et al., 2010; Crose et al., 2009; Richardson et al., 2013; Stockton
et al., 2010; Whitehead et al., 2009; Zheng et al., 2010). Indeed,
the identiﬁcation of this causal pathogenic mechanism has sug-
gested a potential therapy for CCM disease based on inhibitors of
RhoA activation and signaling, including statins and fasudil (Li and
Whitehead, 2010; McDonald et al., 2012).
In addition, there is evidence that CCM proteins ensure the
quiescence of endothelial cells and inhibit angiogenic responses
by either activating the Delta-Notch signaling axis (Schulz et al.,
2015; Wustehube et al., 2010; You et al., 2013), inhibiting vascular
endothelial growth factor (VEGF) and MAPK/ERK signaling (Cullere
et al., 2015; DiStefano et al., 2014; Zhu et al., 2010), or preventing
the 1 integrin-dependent activation of a mechanotransduction
pathway mediated by the blood ﬂow-sensitive transcription factor
Kruppel-like factor 2 (KLF2) (Renz et al., 2015).
Taken together, these results raise the intriguing possibility that
CCM proteins orchestrate the signaling crosstalk between inte-
grins and cadherins that coordinately regulates cell–matrix and
cell-cell interactions and actin cytoskeleton dynamics involved in
the control of vascular morphogenesis and homeostasis, thereby
promoting the maintenance of vascular integrity and barrier func-
tion. Consistently, the small GTPase Rap1, a major KRIT1 molecular
interactor (Glading et al., 2007; Serebriiskii et al., 1997), has been
previously reported to play a pivotal role in the signaling network
underlying the functional crosstalk between cadherins and inte-
grins (Balzac et al., 2005; Retta et al., 2006).
Loss-of-function of CCM proteins has also been shown to
trigger -catenin and transforming growth factor beta/bone
morphogenetic protein (TGF/BMP) signaling-driven endothelial-
to-mesenchymal transition (EndMT) (Bravi et al., 2016, 2015; Guan
and Couldwell, 2013; Maddaluno et al., 2013), as well as activation
of MEKK3 signaling and increased expression of the mechanosen-
sitive transcription factors KLF2 and KLF4 (Cullere et al., 2015;
Cuttano et al., 2016; Fisher et al., 2015; Zhou et al., 2015; Zhou et al.,
2016). Both of these mechanisms have been suggested to be key
determinants of CCM disease pathogenesis (Maddaluno et al., 2013;
Bravi et al., 2016; Cuttano et al., 2016; Zhou et al., 2016). Moreover,
it has been also suggested that increased Rho activity, as well as pro-
teolytic activity of extracellular matrix metalloprotease ADAMTS,
arises secondary to increased MEKK3–KLF2/4 signaling during CCM
formation (Zhou et al., 2016). However, while the causal role of
these putative downstream effectors remains to be clearly deﬁned
(Zhou et al., 2016), there is some inconsistency between recent
reports regarding the role of MEKK3 in the regulation of Rho sig-
naling (Fisher et al., 2015; Zhou et al., 2016), as well as the putative
relationship between the MEKK3-KLF4 signaling axis and EndMT
in disease pathogenesis (Cuttano et al., 2016; Zhou et al., 2016).
Furthermore, the functional signiﬁcance of the contrasting effects
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f complete (Fisher et al., 2015) and partial (Zhou et al., 2016)
ndothelial-speciﬁc loss of MEKK3 on ICH and brain blood vessels
eakage in neonatal mouse models remains ambiguous and open to
istinct interpretations (see Section 7).
In this intricate mechanistic scenario, a further level of complex-
ty is added by the discovery that CCM proteins modulate distinct
edox-sensitive signaling pathways and mechanisms, including
ro-oxidant and antioxidant pathways and autophagy (Gibson
t al., 2015; Goitre et al., 2010, 2014; Guazzi et al., 2012; Marchi
t al., 2015), and are implicated in molecular and cellular responses
o oxidative stress and inﬂammatory stimuli (Corr et al., 2012;
oitre et al., 2014). However, besides adding mechanistic com-
lexity, these innovative research ﬁndings have also provided a
otential integrative explanation for the pleiotropic effects of CCM
rotein dysfunctions, shedding new light on the mechanisms of
CM pathogenesis and opening new perspectives for disease pre-
ention and treatment (see Sections below for details).
In sum, while the overwhelming majority of mechanistic stud-
es have enhanced our understanding of the molecular mechanisms
ffected by loss-of-function mutations in CCM proteins with con-
equent implications for the development of distinct potential
harmacological approaches for CCM disease (Table 1), the full clin-
cal impact of this knowledge has so far remained unclear. Indeed,
he causal role in CCM pathogenesis and the mechanistic intercon-
ection of the multiple molecules and mechanisms that have been
roposed as downstream effectors of CCM proteins remain to be
learly deﬁned. Furthermore, most of these studies have not been
ble to explain the clear discrepancy between the pan-endothelial
oss of CCM proteins and the focal nature of CCM lesions in neonatal
ouse models (Boulday et al., 2011; Chan et al., 2011; Gibson et al.,
015; Zhou et al., 2016), leaving open the possibility that additional
ocal determinants of lesion development are required.
. Redox signaling and oxidative stress: the two emerging
aces of CCM protein functions and CCM disease
athogenesis
Structural and functional alteration of brain capillaries, a patho-
ogic hallmark of CCM disease, may  reﬂect both physical and
iochemical changes involving all components of the neurovascu-
ar unit (NVU) (Girouard et al., 2007; Hawkins and Davis, 2005). This
nit consists of cerebral microvascular endothelial cells, astrocytes,
ericytes, and extracellular matrix, which constitute the structural
asis of the BBB and work together to maintain the integrity of brain
apillaries and BBB restrictive features (Clatterbuck et al., 2001).
espite the exact physiological roles of CCM proteins in brain cap-
llaries have not yet been fully deﬁned, several studies in cellular
nd animal models have demonstrated that endothelial expres-
ion of the CCM proteins is crucial for proper angiogenesis and
lood vessel structural and functional maintenance, supporting the
otion that CCM lesions arise because of primary defects intrinsic
o the endothelium (Boulday et al., 2009; He et al., 2010; Liu et al.,
011a; Whitehead et al., 2009, 2004; Zhu et al., 2010). However,
here is also evidence that either astrocyte or pericyte dysfunc-
ions can contribute to the pathogenesis of CCM disease (Louvi
t al., 2011; Schulz et al., 2015; Sweeney et al., 2016), suggesting
hat CCM lesions may  develop as a result of altered structural and
unctional interactions within the NVU due to the combination of
enetic predisposition with a local stressful event.
Among local stress events that might account for a sort of
icro-environmental second hit, triggering CCM lesion formation
n sensitive NVUs of CCM mutation carriers, there is oxidative
tress. This may  be caused locally by an imbalance of the physiolog-
cal equilibrium between the production of reactive oxygen species
ROS), such as superoxide anion (O2•−), hydrogen peroxide (H2O2)iochemistry & Cell Biology 81 (2016) 254–270
and organic hydroperoxides, and the ability of cellular antioxidant
mechanisms to readily detoxify the reactive intermediates or repair
the resulting damage (Goitre et al., 2012; Retta et al., 2012). In par-
ticular, the superoxide anion (O2•−) is the key determinant of the
overall effects of ROS, being the precursor of all other major reactive
oxygen species found in biological systems, including the powerful
oxidants hydroxyl radical (•OH), hydrogen peroxide (H2O2), and
peroxynitrite (OONO−) (Goitre et al., 2012; Wolin et al., 2002).
Within an intermediate physiological range of concentrations,
ROS function as critical signaling molecules implicated in vari-
ous cell fate decisions and signal transduction pathways, including
regulation of cell metabolism, adhesion, migration, proliferation,
differentiation and survival (Dodson et al., 2015; Holmstrom and
Finkel, 2014). On the other hand, it is well understood that exces-
sively high levels of ROS may  cause ‘oxidative stress’ that induces
damage to proteins, membrane lipids and nucleic acids, lead-
ing eventually to cellular dysfunctions and diseases. Nevertheless,
there is increasing evidence that pathological effects can also be
evoked by excessively low levels of ROS due to the sustained activa-
tion of antioxidant pathways, which may cause a ‘reductive stress’
that affects fundamental redox-dependent molecules and molec-
ular mechanisms (Dodson et al., 2015). Thus, the response to ROS
displays hormesis, which should be considered when addressing
the pathophysiological relevance of ROS in diseases, including vas-
cular diseases, as well as therapeutic approaches with exogenously
administered antioxidants or the activation of endogenous antiox-
idant pathways (Dodson et al., 2015; Johansen et al., 2005).
ROS are generated both constitutively, as common by-products
of oxidative metabolism, and in response to the activation of several
oxidative enzyme systems. Speciﬁcally, the redox complexes I and
III of the mitochondrial electron transport chain are the major con-
stitutive source of ROS, converting up to 5% of molecular O2 to O2•−.
In addition, ROS are produced by the activity of NADPH oxidase,
xanthine oxidase (XO), cytochrome p450 monooxygenase (CYP),
uncoupled NO synthase (NOS), myeloperoxidase (MPO), lipoxy-
genase (LOX), and cyclooxygenase (COX) enzymes, which can be
induced by a variety of endogenous and exogenous chemical and
physical stimuli (Goitre et al., 2012). Conversely, the burden of
ROS production is largely counteracted by a number of constitutive
or inducible antioxidant defense systems, whose cytoprotective
functions are essential to prevent and counteract oxidative stress,
thus maintaining or restoring cellular homeostasis (Espinosa-Diez
et al., 2015). In particular, mitochondria, the most powerful source
of ROS, are endowed with a heavy presence of non-enzymatic
antioxidants and antioxidant enzymes, including the superoxide
dismutase 2 (SOD2) enzyme, which plays a major role in antioxi-
dant defenses by catalyzing the dismutation of O2•− into H2O2 and
O2. In turn, H2O2 is reduced to H2O by the catalase and glutathione
peroxidase enzymes (Fukai and Ushio-Fukai, 2011; Goitre et al.,
2012). In addition, the recognition of dysfunctional mitochondria
and their selective targeting for degradation by a speciﬁc mode of
autophagy, termed mitophagy, has evolved as a defense mecha-
nism of quality control that avoids the accumulation of damaged,
ROS-generating mitochondria, thereby contributing to maintain
cellular redox homeostasis (Lee et al., 2012; Scherz-Shouval and
Elazar, 2011).
All cellular components of NVUs have been shown to generate
ROS. Indeed, it is now well established that physiologic concentra-
tions of ROS are endowed with fundamental signaling properties,
which are essential for both normal cellular homeostasis and adap-
tation to changes of the microenvironmental conditions within the
NVU. This signaling capacity is mainly due to the reversible oxi-
dation of speciﬁc redox-sensitive molecular targets, which act as
components of redox-sensitive signal transduction pathways to
fulﬁll a wide range of essential biological functions (Goitre et al.,
2012). In contrast, abnormal levels of ROS may  exert very damag-
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ng effects through oxidative stress, which can result in pathological
xidative modiﬁcations affecting cellular components of the NVU
nd the BBB (Chrissobolis et al., 2011). Pro-oxidant factors and
xidative stress may  be produced at NVUs following local metabolic
nd biochemical changes, inﬂammatory responses, impaired neu-
ovascular coupling, and ischemia/hypoxia events, as well as by
xogenous oxidative insults, including cell exposure to xenobiotics
r ionizing radiation, resulting in BBB dysfunction (Chrissobolis
t al., 2011; Freeman and Keller, 2012; Goitre et al., 2012). There
s now a wealth of evidence indicating that oxidative stress is
ndeed a major cause of vascular remodeling and NVU dysfunc-
ion associated with cerebrovascular diseases (Chrissobolis et al.,
011; Faraci, 2011; Fraser, 2011). In particular, oxidative stress
as been clearly implicated in all the major molecular and cellu-
ar alterations related to CCM diseases, including destabilization
f endothelial cell-cell junctions, increased 1 integrin activation,
educed cellular ability to maintain a quiescent state, increased vas-
ular permeability, and angiogenic activity (Fraser, 2011; Fukai and
shio-Fukai, 2011; Goitre et al., 2012; Ushio-Fukai, 2009), suggest-
ng that it may  represent a signiﬁcant triggering factor involved in
he initiation and progression of CCM disease. Consistently, CCM
roteins have been involved in protecting cells against oxidative
tress (Fidalgo et al., 2012; Goitre et al., 2010, 2014), raising the
ossibility that CCM lesions may  result from an impaired oxidative
tress defense in microvascular districts of genetically predisposed
ubjects, and opening new therapeutic perspectives (Gibson et al.,
015; Goitre et al., 2010, 2014; Moglia et al., 2015; Moglianetti et al.,
016).
Speciﬁcally, it was originally demonstrated that KRIT1 plays
n important role in maintaining intracellular ROS homeostasis,
hereby limiting molecular and cellular oxidative dysfunctions and
reserving cellular resistance to oxidative stress (Goitre et al.,
010). This antioxidant and cytoprotective role was  associated with
he KRIT1-dependent maintenance of mitochondrial homeostasis
nd modulation of master regulators of cell responses to oxidative
tress, including the transcriptional factor FoxO1, its downstream
arget and major cellular antioxidant enzyme SOD2, and Sirt1
Goitre et al., 2010). These original ﬁndings have been then sub-
tantiated by the identiﬁcation of a novel molecular interactor of
RIT1, the Kelch family protein Nd1-L, which was previously impli-
ated in the regulation of both Rho GTPases and cellular responses
o oxidative stress (Guazzi et al., 2012), as well as by the discovery
hat also CCM3/PDCD10 plays a role in protecting cells from oxida-
ive stress (Fidalgo et al., 2012). In particular, PDCD10 is required
or the activation of the GCKIII kinase Mst4 and its relocation to the
ell periphery after oxidative stress, where it phosphorylates and
ctivates ezrin/radixin/moesin (ERM) proteins, thereby promoting
ell survival (Fidalgo et al., 2012). Furthermore, these ﬁndings have
een subsequently consolidated and extended by novel ﬁndings
howing that KRIT1 may  exert a protective role against oxidative
tress by limiting pro-oxidant and pro-inﬂammatory pathways,
ncluding JNK/c-Jun-dependent redox signaling, and consequent
olecular and cellular dysfunctions (Goitre et al., 2014). Indeed,
t has been demonstrated that KRIT1 loss-of-function causes the
p-regulation of c-Jun, a basic component of the dimeric redox-
ensitive transcription factor AP-1, both in cellular models and
uman CCM tissue samples; conversely, this up-regulation can be
eversed by either KRIT1 re-expression or ROS scavenging with
ntioxidant compounds (Goitre et al., 2014). Notably, overexpres-
ion of KRIT1 prevented forced up-regulation of c-Jun induced by
xidative stimuli, suggesting an essential, dose-dependent role for
RIT1 in protecting cells against exogenous oxidative insults by
imiting c-Jun-dependent redox pathways (Goitre et al., 2014). In
ccord with these ﬁndings, there is clear evidence that the redox-
ensitive transcription factor c-Jun is up-regulated in response to
ither oxidants or oxidative stress (Kunsch and Medford, 1999;iochemistry & Cell Biology 81 (2016) 254–270 259
Lee et al., 1996). c-Jun is also associated with vascular dysfunc-
tion, including enhanced vascular remodeling and permeability,
and inﬂammatory responses (Lum and Roebuck, 2001; Rojas et al.,
2006), as well as with pathological angiogenesis and microvascu-
lar diseases in humans (Fahmy et al., 2006; Folkman, 2004; Zhang
et al., 2004, 2006). Interestingly, the up-regulation of c-Jun conse-
quent to KRIT1 loss-of-function is accompanied by the induction of
cycloxygenase 2 (COX-2), a major oxidative stress biomarker and
inﬂammatory mediator involved in vascular dysfunctions (Hsieh
et al., 2012; Ushio-Fukai and Nakamura, 2008), raising the possi-
bility that KRIT1 loss-of-function might be implicated in synergistic
oxidative stress and inﬂammatory responses (Goitre et al., 2014).
Indeed, consistent with a potential role for inﬂammatory processes
in CCM disease pathogenesis, mice heterozygous for the deletion
of the KRIT1 gene (KRIT1+/−) exhibit an enhanced sensitivity to
inﬂammatory stimuli (Corr et al., 2012), and there is evidence that
inﬂammatory response occurs in CCM lesions (Shenkar et al., 2007;
Shi et al., 2009) (see Sections 4, 5 and 7).
Both the original ﬁndings linking KRIT1 to the control of redox-
sensitive signaling pathways, and the original hypothesis that
loss-of-function mutations of CCM genes may  predispose endothe-
lial cells to oxidative stress-mediated dysfunctions (Goitre et al.,
2010, 2014) have gained strong support from a recent integrated
and cooperative research approach based on cellular and ani-
mal  models of loss-of-function of CCM2 (Gibson et al., 2015). In
particular, this study demonstrated that CCM2 loss-of-function
in endothelial cells induces increased ROS and decreased FoxO1
expression (Gibson et al., 2015), reﬂecting physiopathologic mech-
anisms common to KRIT1 (Goitre et al., 2010), and provided
evidence that oxidative stress may  be a driving force in CCM at the
level of individual cells (Gibson et al., 2015). Importantly, this study
suggested also new promising preventive and therapeutic options
based on two available repurposed drugs: Tempol, a SOD-mimetic
ROS scavenger (Pires et al., 2010), and cholecalciferol (vitamin D3),
a physiological compound endowed with autophagy-inducing and
antioxidant properties that has been shown to exert protective
effects against oxidative injury in various cell types, including vas-
cular endothelial cells, neurons and glial cells (Garcion et al., 2002;
Hoyer-Hansen et al., 2010; Ting and Lee, 2013; Wiseman, 1993). In
particular, cell treatment with these compounds was effective in
reversing the hyperactivation of RhoA and consequent biological
outcomes induced by CCM2 knockdown, including actin stress ﬁber
formation, adherens junction weakening, and endothelial barrier
dysfunction (Gibson et al., 2015). Moreover, both these compounds
showed an enhanced effectiveness in decreasing lesion burden in
a mouse model of CCM disease (Gibson et al., 2015), as compared
to the previously reported putative therapeutic beneﬁts of statins
(Li and Whitehead, 2010; Whitehead et al., 2009).
In this light, the reported role of the TGF- pathway in CCM
disease pathogenesis (Maddaluno et al., 2013) might be connected
to, and downstream of deregulation of oxidative stress and c-Jun
activity. Indeed, there is clear evidence that ROS can stimulate
the activation of the TGF- pathway with important consequences
on cellular functions (Fukawa et al., 2012; Gonzalez-Ramos et al.,
2012), and it has also been demonstrated that this ROS-mediated
regulation is dependent on c-Jun transcriptional activity (Gonzalez-
Ramos et al., 2012). Furthermore, the established functions of CCM
proteins in the regulation of both cadherin- and integrin-mediated
cell adhesion and RhoA-dependent actin cytoskeleton dynamics
might be directly related to the emerging important role of ROS
and redox signaling in the modulation of the functional crosstalk
between cadherins, integrins and small GTPases (Ferro et al., 2012;
Goitre et al., 2012). In particular, it is intriguing that the activa-
tion of redox signaling complexes at integrin-mediated cell-matrix
adhesion sites and cadherin-mediated cell-cell junctions induces
opposite effects, leading to assembly of integrin-mediated focal
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dhesions and disassembly of cadherin-mediated AJs, respectively,
ollowed by morphological transition toward a mesenchymal phe-
otype (Goitre et al., 2012), which recapitulate almost all the major
olecular mechanisms of CCM pathogenesis. Finally, given the
ell-established role of MEKK3 and KLFs as both targets and regu-
ators of redox signaling and cellular responses to oxidative stress
Chen et al., 2015; Hamik and Jain, 2012; Son et al., 2011), also the
ecently reported involvement of the MEKK3-KLF4 signaling axis
n CCM pathogenesis (Cuttano et al., 2016; Zhou et al., 2016) might
mply dysregulation of redox signaling and oxidative stress (see
ections 5 and 7).
Notably, the ﬁndings described above provide also an alterna-
ive explanation to the previously suggested effectiveness of statins
e.g., simvastatin) (Li and Whitehead, 2010), fasudil (McDonald
t al., 2012), and sulindac derivatives (Bravi et al., 2015) as poten-
ial therapy for CCM disease. Indeed, both statins and fasudil have
een shown to reduce the expression and transcriptional activity
f c-Jun (Dichtl et al., 2003; Wang et al., 2011a, 2011b), and there
s evidence that the Rho GTPase pathway can be directly activated
y ROS (Aghajanian et al., 2009; Ferro et al., 2012). Moreover, both
tatins, fasudil and sulindac derivatives are known to exert power-
ul antioxidant activities in endothelial cells, including inhibition
f superoxide production and improvement of ROS scavenging,
hich in some cases was  even more effective than endogenous
ntioxidants such as GSH (Adam and Laufs, 2008; Costa et al., 2005;
uhlmann et al., 2008; Ma  et al., 2011).
Recent ﬁndings have also linked defective autophagy to
nhanced endothelial cell sensitivity to oxidative stress, which
uggests a pathogenetic mechanism that reconciles both the
leiotropic functions of CCM proteins and the distinct therapeutic
pproaches proposed so far (Marchi et al., 2015, 2016a, b). Indeed, it
s well established that autophagy inducers limit ROS accumulation
nd oxidative stress by stimulating the autophagic degradation of
OS-generating mitochondria (Lee et al., 2012; Scherz-Shouval and
lazar, 2011). On the other hand, there is compelling evidence that
ntioxidant compounds, such as those indicated above, can induce
utophagy, including statins (Andres et al., 2014; Wei  et al., 2013;
hang et al., 2013a), fasudil (Iorio et al., 2010), sulindac derivatives
Chiou et al., 2011; Gurpinar et al., 2013), and vitamin D3 (Hoyer-
ansen et al., 2010; Kim et al., 2012; Lisse and Hewison, 2011; Wu
nd Sun, 2011). Together with recent ﬁndings suggesting that the
nterplay between defective autophagy and redox imbalance may
e integral to the development and progression of CCM lesions by
ensitizing endothelial cells to local oxidative stress events (Marchi
t al., 2015), these observations point to autophagy as a major
edox-sensitive mechanism that justiﬁes the reported effectiveness
f the different potential therapeutic compounds described so far
Marchi et al., 2016a, b).
Taken together, these considerations indicate that CCM proteins
re new players in redox biology, and suggest that oxidative stress
ay  contribute signiﬁcantly to the development and progression
f CCM disease by inﬂuencing molecular and cellular mechanisms
nderlying its major phenotypic hallmarks, including destabi-
ization of endothelial cell-cell junctions, increased 1 integrin
ctivation, increased vascular permeability, and enhanced angio-
enic and inﬂammatory responses. In addition, oxidative stress is
lso a likely candidate to drive progression and severity of CCM
isease. Indeed, several genes encoding proteins involved in ROS
etabolism and vascular responses to oxidative stress are char-
cterized by single nucleotide polymorphisms (SNPs) that confer
ubstantial inter-individual variability in susceptibility to various
xidative stress-related pathologies, including vascular diseases
Trapani and Retta, 2015). Consistently, a recent study by Choquet
t al. identiﬁed oxidative stress-related genetic modiﬁers, including
enetic variants in cytochrome P450 mono-oxygenase (CYP) and
xtracellular matrix metalloproteinase (MMP)  genes, that inﬂu-iochemistry & Cell Biology 81 (2016) 254–270
ence the severity of fCCM disease as manifested by ICH and greater
total or large lesion counts (Choquet et al., 2016), suggesting that
inter-individual variability in susceptibility to oxidative stress may
contribute to CCM disease pathogenesis and severity.
Overall, the evidence accumulated so far weighs heavily in favor
of a unifying pathogenic mechanism whereby the loss-of-function
of CCM proteins sensitize vascular cells to local oxidative stress
events, and raises the possibility that inter-individual variability
in susceptibility to oxidative stress may  contribute to CCM disease
pathogenesis.
4. CCM proteins regulate the inﬂammatory response
The idea that susceptibility to microenvironmental elements
and oxidative stress can be conferred to cells by loss-of-function
mutations in CCM proteins suggests that these proteins may  also
play a role in limiting the endothelial response to inﬂammation.
Indeed, as stabilizers of endothelial AJs, CCM proteins are opti-
mally placed to regulate the vascular response to inﬂammation,
as the stability of endothelial cell-cell contacts is a key compo-
nent of vasogenic edema and leukocyte extravasation. Speciﬁcally,
destabilization or increased turnover of endothelial cell-cell con-
tacts increases the net ﬂux of ﬂuid across the endothelial barrier.
This, in turn, carries with it small molecules and proteins that dis-
rupt the osmotic balance between blood and tissue, causing further
ﬂuid ﬂux across the vessel wall. At the tissue level, once the ﬂux of
ﬂuid into the tissue exceeds the ability of the lymphatic vessels
to compensate, ﬂuid accumulates in the tissue, causing edema (Lee
and Liles, 2011). KRIT1 heterozygous animals, which appear pheno-
typically normal, in fact demonstrate increased ﬂux of ﬂuid/protein
out of their vessels at a rate more than double of their wildtype
littermates. However, these mice do not appear edematous, pre-
sumably due to the compensation in ﬂuid management by the
lymphatic vessels (Corr et al., 2012). These animals also develop
more severe reactions to inﬂammatory stimuli, and in fact exhibit
increased sensitivity to auto-antigens and foreign polysaccharides,
demonstrating clearly that loss of KRIT1 decreases the threshold
at which an inﬂammatory response will occur (Corr et al., 2012).
The increase in baseline ﬂuid ﬂux has also been observed in fCCM
patients, which exhibit increased vascular permeability throughout
their brain tissue, not only in areas containing CCM lesions (Girard
et al., 2016; Hart et al., 2013). Mechanistically, the underpinnings
for an enhanced inﬂammatory response are also present in human
patients; therefore it is highly likely that increased sensitivity to
inﬂammatory stimuli also occurs in human patients.
The role of CCM proteins in the vascular response to inﬂam-
mation has only recently been investigated, and is one of the only
functions for CCM proteins described under non-pathological con-
ditions. Existing data points to an anti-inﬂammatory role for CCM
proteins, in which they function to suppress the activation of, or
response to, pro-inﬂammatory signals. As an effector of Rap1, KRIT1
mediates the ability of this GTPase to stabilize endothelial cell-
cell contacts, as has been shown in response to thrombin (Glading
et al., 2007) and acute lung injury (Meliton et al., 2015), thus lim-
iting the inﬂammatory response. Less direct evidence is available
regarding the ability of CCM2 and PDCD10 to regulate the endothe-
lial inﬂammatory response. However, PDCD10 has an emerging
role in the hematopoietic system, where it has been shown to
play a role in neutrophil degranulation and malignant T-cell sur-
vival (Lauenborg et al., 2010; Zhang et al., 2013b). Indeed, KRIT1,
CCM2, and PDCD10 are all widely expressed, including in multi-
ple hematopoietic lineages, pericytes and smooth muscle cells, and
epithelial cells (Glading and Ginsberg, 2010). Thus the role for these
proteins and their requisite complex in inﬂammation is likely to
expand as more studies are performed.
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. Role of inﬂammation in CCM pathogenesis
The pathogenesis of CCM is thought to require genetic loss
f both alleles of a single CCM protein, which leads to abnor-
al  endothelial responses, including changes in cell adhesion,
ytoskeletal rearrangement, transcriptional activity, and oxidative
tress. This is supported by genetic animal models, in which loss
f both alleles of KRIT1, CCM2, or CCM3 is required for the forma-
ion of CCM-like vascular lesions (Boulday et al., 2009; Chan et al.,
011). However, the large variation in disease severity among fam-
ly members carrying the same disease-associated genetic defect
uggests that additional factors other than the disease-causing
utation can contribute to CCM disease pathogenesis. Several lines
f evidence suggest that inﬂammation may  play one or more roles
n the etiology of cerebral cavernous malformations and provide a
ite-speciﬁc, local stimulus for lesion formation or progression.
First, partial loss of CCM proteins increases intracellular ROS lev-
ls and oxidative stress (Goitre et al., 2010), which contribute to
he up-regulation of inﬂammatory transcription factors including
F-B, AP-1, and PPAR-,  leading to the production and release
f cytokines and chemokines (Corr et al., 2012). Second, loss of
ndothelial cell-cell contact, even in heterozygous patients and
nimals, would likely predispose the vasculature to chronic, low-
rade inﬂammation due to intermittent exposure of the vascular
asement membrane, a potent inﬂammatory stimulus (Mackel
t al., 1982). A related example of such a mechanism is observed
n radiation-induced cavernous malformation (RICM) in which
adiation-induced endothelial damage leads to the stimulation of
ro-inﬂammatory signaling, the development of large, often mul-
iple, vascular malformations that closely resemble CCMs, and
emorrhage (Cutsforth-Gregory et al., 2015; Nimjee et al., 2006;
ark et al., 2011). Third, recent evidence suggests that innate
mmune cells contribute to the vascular permeability phenotype
f KRIT1 deﬁcient mice. Transplantation of wildtype bone marrow
nto endothelial KRIT1 knockout animals restored vascular perme-
bility in these animals to wildtype levels. However, the converse
ransfer of knockout bone marrow to wildtype animals did not
ecrease barrier function, suggesting that loss of KRIT1 expression
n both the endothelium and the hematopoietic cell compartment
s required for the phenotypic effects of KRIT1 depletion (Corr et al.,
012). As the interaction between circulating immune cells and the
ndothelium in KRIT1 deﬁcient mice appear normal, this suggests
hat loss of KRIT1 may  alter the signaling capacity of hematopoietic
ells in some other way, such as through increasing the frequency
f the oxidative burst. Interestingly, CCM formation is associated
ith the increased expression of speciﬁc human leukocyte anti-
en types (Sanus et al., 2007), suggesting that there may  also be
 genetic contribution from the immune system that predisposes
o CCM formation. Finally, while the primacy of inﬂammatory sig-
aling to CCM formation has yet to be formally established, it is
mportant to note that the wide variety of molecular mechanisms
ttributed to CCM formation, including down-regulation of cell-cell
ontacts, altered cell-matrix adhesion, activation of RhoA signal-
ng and cytoskeleton contractility, endothelial to mesenchymal
ransition, altered expression levels and activity of various tran-
cription factors, increased oxidative stress, and angiogenesis, all ﬁt
omfortably under the umbrella of known inﬂammatory signaling
echanisms. For these reasons, inﬂammation is a prime candidate
or the putative “microenvironmental hit” required for local CCM
esion formation, and in fact, further examination of the role of
nﬂammation in CCM may  ﬁnally lead to a cohesive mechanism
f lesion development.
In recent years, several downstream pathways have been iden-
iﬁed which are up-regulated in fCCM, or following loss of one or
ore of the CCM proteins in mice, as we brieﬂy summarized in
ection 2 and Table 1. Conspicuously, of those pathways that haveiochemistry & Cell Biology 81 (2016) 254–270 261
been pharmacologically targeted in vivo for their effects on lesion
development, none have been able to provide more than 50% relief
of lesion burden, suggesting that each pathway is only partially
responsible for the CCM phenotype. Notably, signiﬁcant crosstalk
between the inﬂammatory response and many of these pathways
is already suggested by ﬁndings in other ﬁelds. Down-regulation of
cell-cell contacts and activation of RhoA signaling and cytoskele-
ton contractility (Glading et al., 2007; Stockton et al., 2010) occurs
in the absence of CCM proteins, but is also considered a common
downstream consequence of pro-inﬂammatory cytokine signaling
and contributes the most strongly to increases in vascular per-
meability. Increased permeability can contribute to the activation
of junctionally-regulated transcriptional factors, such as -catenin
(Glading and Ginsberg, 2010) and Kaiso (unpublished data), both
seen in the absence of CCM proteins. These can then upregulate
both pro-inﬂammatory and pro-angiogenic signals, such as VEGF
expression (DiStefano et al., 2014), which regulate cellular levels
of oxidative stress (Kim and Byzova, 2014). Altered cell-cell and
cell-matrix adhesion are hallmarks of EndMT, observed in both
CCM protein-deﬁcient cell culture models (Maddaluno et al., 2013)
and human CCM lesions (Bravi et al., 2016), which also leads to
the upregulation of a host of transcription factors, including KLFs
that contribute to the mesenchymal phenotype, but also regulate
-and are regulated by- oxidative stress (Chen et al., 2015; Zucker
et al., 2014). Recent attention has focused on the activation of MAP
kinase signaling, particularly downstream of the scaffold MEKK3,
which is activated in mouse models of CCM, and which binds to
CCM2 (Fisher et al., 2015; Uhlik et al., 2003). Deletion of mouse
MEKK3 leads to loss of neurovascular integrity in neonates (Fisher
et al., 2015), but conditional deletion of MEKK3 in CCM2 knockout
animals prevents CCM-like lesion formation by blocking activation
of KLF4 (Zhou et al., 2016). Notably, MEKK3 is regulated by ROS
(Son et al., 2011), and is part of the NF-B regulatory machinery
downstream of pro-inﬂammatory Toll-like receptors (Qin et al.,
2006) and TNF receptors (Blonska et al., 2005), suggesting that
activation of MEKK3 signaling could be part of the inﬂammatory
response. KLF2 and KLF4 are also tightly associated with endothelial
redox and inﬂammatory balance. Indeed, both KLFs confer vas-
cular protection via regulation of gene programs that result in
an anti-inﬂammatory, anti-coagulant, anti-adhesive, anti-oxidant
state of the endothelium, thus serving as guardians of endothe-
lial health against various stress conditions, including oxidative
stress and inﬂammation (Hamik and Jain, 2012). More speciﬁcally,
these cytoprotective transcription factors are involved in a com-
plex network of redox-sensitive mechanotransduction signaling
that inhibits oxidative stress and inﬂammation while promoting
vascular homeostasis (Chen et al., 2015; Hamik and Jain, 2012),
suggesting that these mechanisms could play a role in CCM disease
pathogenesis (see Section 7). Clearly, there are many tantalizing
hints as to how these pathways work together to promote the
development and progression of CCM, yet there is a large amount
of work to be done to delineate those connections.
The idea that inﬂammation could signiﬁcantly contribute to
the formation of de novo lesions is attractive for several rea-
sons. Chronic inﬂammation is known to stimulate a proliferative
and angiogenic phenotype, such as that observed in the pan-
nus of rheumatoid arthritis (Szekanecz et al., 2005). Consistently,
heterozygous KRIT1 mouse embryos and human CCM lesions
exhibit increased endothelial proliferation (Shenkar et al., 2005;
Whitehead et al., 2004). Consequently, enhanced proliferation
could promote the further loss of CCM protein expression due
to ampliﬁcation of the innate error rate- the putative 2nd hit.
Inﬂammatory signaling also causes changes in gene expression
that stimulate ﬁbrosis, both at the level of endothelial extracel-
lular matrix (ECM) secretion and downstream of EndMT (Moonen
et al., 2015). Fibrotic changes, which are commonly observed in
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CM lesions of mice and humans (Bicer et al., 2010; Clatterbuck
t al., 2001; Faurobert et al., 2013), promote EndMT and endothe-
ial proliferation and could also provide a secondary signal driving
own-regulation of cell-cell contacts, increased proliferation, and
igration due to altered signaling from the ECM. Lastly, the focused
ature of inﬂammation, which is typically conﬁned to a local
rea, could provide an explanation for the focal nature of CCM.
s described above, in genetic animal models in which loss of
CM proteins occur in over 80% of endothelial cells as measured
y Cre-mediated recombination, lesions comprise <5% of the total
ascular bed (Chan et al., 2011). Furthermore, human CCM tissues
nly contain a second somatic mutation in 10–15% of cells (Akers
t al., 2009), suggesting that lesion development may  involve
on-cell autonomous epigenetic signaling events. Thus inﬂam-
ation/inﬂammatory signaling could help drive lesion formation
y promoting a cellular context in which genetic events could
rive changes in the local neurovascular environment that lead to
ndothelial proliferation, reduced vessel integrity, and ultimately
istorted vascular morphology.
Inﬂammation is also a likely candidate to drive progression of
CM lesions. Overwhelming evidence suggests that CCM lesions
re highly dynamic, and can grow and shrink in size as well as
ary in hemorrhage rate and severity (Acciarri et al., 2009; Jung
t al., 2003; Yadla et al., 2010). A recent study by Choquet et al.
dentiﬁed common genetic variations in inﬂammatory and immune
esponse pathways in patients with fCCM that correlated with hem-
rrhage, lesion size and lesion number, strongly suggesting that
enetic variation in the inﬂammatory response can inﬂuence dis-
ase severity and variability (Choquet et al., 2014b). Indeed, the
onnection between inﬂammation and hemorrhage is well estab-
ished in multiple cerebrovascular disorders, including cerebral
schemia (Ahmad et al., 2014), congenital and trauma-induced
neurysm (Kataoka, 2015), cerebral arteriovenous malformation
AVM) (Mouchtouris et al., 2015), and cerebral amyloid angiopathy
Castro Caldas et al., 2015). Anti-inﬂammatory treatment of these
onditions reduces bleed rate and severity. However it is difﬁcult,
ven in these cases, to distinguish between inﬂammation preceding
he hemorrhagic event, and the inﬂammatory response generated
y the hemorrhage. Thus in CCM lesions, where there is direct evi-
ence of the presence of an innate inﬂammatory response within
arge, mature lesions, it remains unclear when the inﬂammatory
esponse occurred during the natural history of the lesion. Never-
heless, it is clear that inﬂammatory cells accumulate within CCM
esions and therefore may  signiﬁcantly contribute to disease phe-
otype (Shi et al., 2009). Curiously, CCM lesions accumulate mast
ells, T- and B-cells, in addition to the neutrophils and macrophages
hat are more typical of the acute inﬂammatory response (Hagiwara
t al., 1999; Shi et al., 2009). Indeed, inﬁltration of neutrophils
nd macrophages are common to many cerebrovascular disorders,
uch as AVM (Chen et al., 2008); however, the accumulation of
-cells- and particularly B-cells- is relatively uncommon, and is
ore often seen in chronic inﬂammatory conditions involving the
uto-immune response, such as rheumatoid arthritis and multi-
le sclerosis (Alunno et al., 2015; Ireland et al., 2015). Multiple
tudies by Shi et al. have identiﬁed the presence of oligoclonal B-
nd plasma cell populations within some CCM lesions (Shi et al.,
007). More recently, they have shown that B-cell depletion can
educe the progression of CCM-like lesions in vivo (Shi et al., 2016).
hile the antigen or antigens recognized by these cellular inﬁl-
rates remains unknown, their presence presents a striking parallel
o the ectopic B-cell clonal expansion seen in some forms of multi-
le sclerosis (Owens et al., 2003), raising the possibility that chronic,
uto-immune mediated inﬂammation contributes to the forma-
ion or progression of CCM, and that mitigating this destructive
nﬂuence could be an effective form of treatment for this disease.iochemistry & Cell Biology 81 (2016) 254–270
Clearly, the hypothesis that inﬂammation contributes to the
development of CCM is worthy of careful consideration and active
pursuit. Future studies will be necessary to validate the ability
of inﬂammation to stimulate de novo lesion development, which
will require use of novel mouse models and careful experimen-
tal design. However, analysis of existing patient records may yield
indirect evidence of inﬂammation during disease progression. One
such study tracked symptom onset in a small population of patients
and found that over 60% of patients presented with symptoms dur-
ing the fall and winter ﬂu season, suggesting the possibility that
sub-clinical viral infection could create the appropriate cellular
context for disease progression (Flemming et al., 2015). Alterna-
tively, the authors of this study suggested that the correlation could
be caused by vitamin D deﬁciency, a potent antioxidant, during
cloudy winter months, particularly intriguing given that vitamin D
reduces lesion burden in mouse models of CCM (Gibson et al., 2015).
Regardless of the cause, it is clear that there is still much to ascer-
tain regarding the contribution of inﬂammation to CCM, with the
hope that eventually the great catalog of anti-inﬂammatory drugs
could be mined for new treatments for CCM.
6. Role of angiogenesis in CCM pathogenesis
Inﬂammatory stimulation, particularly chronic inﬂammation, is
intimately linked with angiogenesis in the adult. Angiogenesis, the
process of forming new vessels from pre-existing vessels, occurs
in many tissues in response to hypoxia or tissue injury. Sprout-
ing angiogenesis occurs in response to angiogenic growth factors
(VEGF, bFGF, etc.), and requires the remodeling of the endothe-
lial cytoskeleton, cell-matrix adhesion, and cell-cell contacts (for
review, see (Kushner and Bautch, 2013)). Inﬂammatory cytokines
can up regulate pro-angiogenic signaling pathways and stimu-
late endothelial proliferation. In addition, increased permeability
is considered a precursor to angiogenesis and is activated by pro-
angiogenic signals (Nagy et al., 2008). Disassembly of AJs, such as
after endothelial exposure to activated neutrophils, is accompanied
by the release of −catenin from cell junctions (Potter et al., 2005;
Tinsley et al., 2002) and is required for angiogenesis and vascular
remodeling (Carmeliet et al., 1999; Wallez and Huber, 2008).
As regulators of endothelial AJ stability, CCM proteins are poised
to be key negative regulators of angiogenesis, which has been
closely examined in multiple studies. KRIT1, CCM2, and PDCD10
are required for vascular development, as homozygous deletion
of each of these proteins causes embryonic lethality between E8.5
(KRIT1, CCM2) and E12.5 (PDCD10) (Chan et al., 2011; Whitehead
et al., 2004). The severity of the defects in these animals makes
it difﬁcult to determine where and when in vascular development
CCM proteins are critical. However in zebraﬁsh, mutation or down-
regulation of KRIT1 or CCM2 expression causes increased sprouting
and failed lumenization of somatic vessels in addition to a dilated
heart phenotype (Hogan et al., 2008; Liu et al., 2010; Whitehead
et al., 2009). In contrast, loss of CCM3 causes malformation and
dilation of newly formed cerebral vessels, but not heart dilation
(Schleider et al., 2011). In vitro, studies using isolated endothelial
cells have yielded somewhat contradictory ﬁndings. While some
studies have shown that loss of KRIT1 or CCM2 inhibit the ability of
human umbilical vein endothelial cells (HUVEC) to form tube-like
structures (Liu et al., 2010; Whitehead et al., 2009; Zhu et al., 2010),
others have shown that loss of KRIT1 causes increased endothe-
lial sprouting, proliferation and migration (Wustehube et al., 2010).
Knockdown of PDCD10 however, appears to consistently increase
tube formation in both HUVEC and human brain microvascular
endothelial cells (Schleider et al., 2011; Zhu et al., 2010). PDCD10
is also important for endothelial cell polarization and lumen for-
mation through its interactions with members of the STRIPAK
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Fig. 2. Schematic model of the relationship between loss-of function of a CCM protein and major phenotypes associated with CCM disease—Toward a unifying mechanistic
scenario for CCM disease pathogenesis and treatment.
CCM proteins play pleiotropic roles in distinct redox-sensitive pathways by modulating the ﬁne-tuned crosstalk between redox signaling and autophagy. Effective autophagy
removes ROS-generating cellular trash, including damaged mitochondria, to rejuvenate cell environment, thus serving a cytoprotective function for the maintenance of
endothelial cell monolayer integrity and functionality and BBB stability even under adverse stress conditions. Loss-of-function of a CCM protein causes defective autophagy
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While these studies support the idea that CCM proteins are
mportant regulators of angiogenesis, many of these studies
ailed to address the mechanism for CCM protein involvement in
ngiogenesis. Nonetheless, increased expression of several pro-
ngiogenic growth factors have been found in human CCM lesions,
ncluding VEGF, PDGF, and TGF- (Abe et al., 2009; Jung et al.,
003; Maiuri et al., 2006; Yildirim et al., 2010), and increased
EGF expression has also been measured in KRIT1 deﬁcient ani-
als (Corr et al., 2012). DiStefano et al. showed that loss of
RIT1 increases VEGF expression by increasing nuclear -catenin
DiStefano et al., 2014), where -catenin stimulates transcrip-
ion of VEGF (Glading and Ginsberg, 2010). The increase in VEGF
xpression leads to autocrine binding of VEGFR2 and subsequent
ctivation of downstream angiogenic signaling pathways, suggest-
ng that VEGF expression contributes to a feed-forward pathway
romoting the CCM pathologic phenotype. Intriguingly, this study
lso pointed out that PDCD10, but not CCM2, also increases -
atenin transcriptional activity and VEGF expression (DiStefano
t al., 2014). However, PDCD10 deﬁcient cells reportedly exhibit
 loss of VEGFR2 signaling and are unable to respond to VEGF stim-
lation (He et al., 2010). Alternatively, both KRIT1 and PDCD10
eﬁcient animals exhibit activation of TGF/BMP signaling down-
tream of -catenin, which promotes EndMT, altered endothelial
olarity, and abnormal vessel formation (Guan and Couldwell,
013; Lampugnani et al., 2010; Maddaluno et al., 2013). Blocking
GF- signaling or -catenin signaling can reduce CCM-like lesion
ormation in KRIT1 and PDCD10 deﬁcient mouse models, respec-
ively (Bravi et al., 2015; Guan and Couldwell, 2013; Lampugnani
t al., 2010; Maddaluno et al., 2013). Wustehube et al. demon-
trated that down-regulating KRIT1 expression suppressed Dll4
nd the expression of Notch-dependent genes, increasing angio-
enic sprouting, and that conversely over-expression of KRIT1
p-regulated Notch activity (Wustehube et al., 2010). Deﬁcientocal oxidative stress and inﬂammatory events, which may  act as key pathogenic
to modulate the interplay between autophagy and redox signaling reconciles the
tment.
Notch activity has also been seen in the absence of PDCD10 (You
et al., 2013). However, no studies have examined Notch signaling in
the absence of CCM2, thus it remains unclear whether all members
of the CCM family ubiquitously regulate this pathway.
Taken together, this data strongly suggests that the CCM com-
plex is a key regulator of angiogenesis as well as postulates a role
for angiogenesis in the formation of CCM lesions. The formation of
new lesions, may  occur via a hijacking of the angiogenic process in
which new vessel formation is subverted to form dilated cavernous
vessels. The increase in expression of angiogenic growth factors in
human CCM patients, and the correlation of VEGF expression with
disease progression, certainly supports the idea that these mech-
anisms may  be active during CCM formation. However, the work
done to date has not deﬁned exactly how this complex regulates the
angiogenic process. More studies will be required to sort out the rel-
ative contributions of KRIT1, CCM2, and PDCD10 to the angiogenic
process, and of neo-angiogenesis to the etiology of CCM.
7. Interplay between oxidative stress and inﬂammation in
CCM disease: towards a comprehensive and integrated
model of pathogenesis and therapeutic approaches
Because of the diversity of molecules and molecular mecha-
nisms that can be modulated by CCM proteins, it is not a surprise
that these proteins inﬂuence almost all aspects of endothelial biol-
ogy, including vascular development, maintenance of endothelial
cell homeostasis, and barrier function (Corr et al., 2012; Glading
et al., 2007; Maddaluno et al., 2013; Whitehead et al., 2009; Zheng
et al., 2010). On the other hand, the emerging pleiotropic func-
tions of CCM proteins in the modulation of various redox-sensitive
signaling pathways, and the accumulating evidence that oxidative
stress, inﬂammation and angiogenesis may  contribute signiﬁcantly
to the onset, progression and severity of CCM disease raise the ques-
tion as to whether the underlying mechanisms are interconnected.
Consistent with this possibility, growing evidence demonstrates
that indeed an intricate, reciprocal relationship exists between
these processes, especially in human pathologies (Kim and Byzova,
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014; Kim et al., 2013b). Speciﬁcally, there is clear evidence that
OS and oxidative stress originating from various sources, includ-
ng cell exposure to chemicals, drugs, or other agents that alter
he cellular redox status, can lead to inﬂammation by activating a
ariety of redox-sensitive transcription factors, including NF-B,
P-1, PPAR-,  and HIF-1,  which drive the expression of pro-
nﬂammatory genes, leading to induction of various cytokines and
hemokines, such as Cell Adhesion Molecules, MCP-1, TNF-, IL-
, and TGF- (Kim et al., 2013b; Miller et al., 2010; Reuter et al.,
010). Moreover, ROS can also induce post-translational modiﬁ-
ation of proteins involved in important redox-sensitive signaling
ransduction pathways that modulate inﬂammatory and angio-
enic responses, including Src, Ras, RhoA/RhoA kinase (ROCK),
I3 K, VEGF, and MAPK pathways (Ferro et al., 2012; Goitre et al.,
012; Ushio-Fukai and Nakamura, 2008). Conversely, production
f ROS can result from activation of immune and endothelial cells
y pro-inﬂammatory stimuli (Basuroy et al., 2009; Kim et al.,
013b). Indeed, although not viewed as typical immunogenic cells,
ndothelial cells are suggested to be sentinel cells that detect
anger signals, initiate innate immune responses, produce pro-
nﬂammatory cytokines and chemokines, and recruit immune cells.
uch increase in the endothelial innate immunity has emerged as
n important mechanism underlying the interplay among oxida-
ive stress, inﬂammation and endothelial dysfunction (Chen et al.,
015). In addition, besides the well-established mechanistic con-
ection between inﬂammation and angiogenesis, there is also clear
vidence that ROS may  promote angiogenesis, either directly or
ia the generation of active oxidation products, including peroxi-
ized lipids (Kim and Byzova, 2014). Accordingly, ROS have been
mplicated both in physiological and pathological angiogenesis,
nd shown to modulate vascular remodeling and inﬂammatory
esponses (Chen et al., 2015; Fukai and Ushio-Fukai, 2011; Miller
t al., 2010; Ushio-Fukai, 2009; Ushio-Fukai and Nakamura, 2008).
emarkably, experimental support that synergistic oxidative stress
nd inﬂammatory responses are indeed implicated in CCM disease
athogenesis was provided by the ﬁnding that the redox-sensitive
p-regulation of c-Jun induced by KRIT1 loss-of-function was
ccompanied by the induction of COX-2, a major inﬂammatory
ediator involved in vascular dysfunction (Goitre et al., 2014)
see Section 3). Consistently, whereas a close relationship between
xidative stress and local inﬂammation has been shown to under-
ie vascular disease of diverse etiology (Basuroy et al., 2009; Faraci,
011; Kim et al., 2013b; Miller et al., 2010), accumulating evi-
ence suggests that both oxidative stress (Gibson et al., 2015; Goitre
t al., 2010, 2014) and inﬂammation (Corr et al., 2012; Shenkar
t al., 2007; Shi et al., 2009, 2016) play a critical role in CCM dis-
ase pathogenesis. On the other hand, it has been also suggested
hat neoangiogenic events may  be necessary to cause CCM dis-
ase (Boulday et al., 2011). Taken together with the established
olecular links and the emerging reciprocity between oxidative
tress, inﬂammation and angiogenesis (Kim and Byzova, 2014;
im et al., 2013b; West et al., 2010), these observations point to
ultifactorial and interconnected mechanisms whereby oxidative
tress, inﬂammation and angiogenesis play key synergistic roles
n CCM pathogenesis, with oxidative stress having potential pri-
acy (Goitre et al., 2014). In accord with this latter possibility,
ecent evidence in animal models has suggested that oxidative
tress may  play an even more critical role in CCM disease than
reviously described due to systemic effects (Gibson et al., 2015).
inally, the recent ﬁndings that genetic variants of modiﬁer genes
elated to oxidative stress and inﬂammatory responses are asso-
iated with phenotypic markers of CCM disease severity, suggest
hat inter-individual variability in susceptibility to either oxidative
tress or inﬂammation may  contribute to CCM disease pathogenesis
Choquet et al., 2014b, 2016).iochemistry & Cell Biology 81 (2016) 254–270
The potential existence of a unifying mechanism that connects
both the pleiotropic functions and the dysfunctional effects of CCM
proteins has clearly emerged from recent discoveries in cellular
and animal models and surgical CCM samples. In particular, the
discovery that defective autophagy is a common feature of loss-
of-function of the three known CCM genes and may  underlie the
major phenotypic hallmarks of CCM disease suggests a potential
unifying pathogenic mechanism that reconciles both the broad
spectrum of signaling abnormalities and consequent pathologic
effects linked to CCM protein dysfunctions, and the distinct thera-
peutic approaches proposed so far (Marchi et al., 2015, 2016a, b).
Indeed, most of the reported pleiotropic functions and dysfunc-
tional effects of CCM proteins are directly or indirectly related
to autophagy and its tight interconnection with redox homeo-
stasis and signaling (Filomeni et al., 2015; Marchi et al., 2016b;
Scherz-Shouval and Elazar, 2011), suggesting that the modulation
of autophagy may  represent an underlying and unifying mecha-
nism for CCM protein physio-pathological functions. Consistently,
autophagy is a converging point of multiple physiological and
pathological pathways and may exert pleiotropic effects on sev-
eral molecular and cellular processes (Choi et al., 2013). Speciﬁcally,
autophagy plays a pivotal role in various signaling pathways linked
to CCM proteins, including pathways involving Sirt1/FoxO1 (Liu
et al., 2015; Zhao et al., 2010), JNK/c-Jun (Yogev and Shaulian, 2010),
RhoA/ROCK (Mleczak et al., 2013), -catenin (Lin et al., 2015), TGF-
 (Marchi et al., 2015), MEKK3 (Linares et al., 2015), and KLF2/4
(Guixe-Muntet et al., 2016; Liao et al., 2015). Moreover, most phe-
notypic hallmarks of CCM disease can be linked to autophagic
dysfunctions, including enhanced ROS production (Huang et al.,
2011; Marchi et al., 2015) and EndMT (Marchi et al., 2015), as well as
altered cell adhesion and angiogenic potential (Kim et al., 2013a;
Kumar et al., 2013; Tuloup-Minguez et al., 2013), and enhanced
endothelial cell sensitivity to oxidant-induced injury (Liu et al.,
2015). Furthermore, recent insights point toward an important role
of autophagy in the endothelial protective effects of several drugs
known to confer vasoprotection, including simvastatin, vitamin D
and other potential therapeutic compounds proposed so far for
CCM disease prevention and treatment (Andres et al., 2014; Guixe-
Muntet et al., 2016; Hoyer-Hansen et al., 2010; Lin et al., 2013;
Marchi et al., 2016a, b). On the other hand, it is now becoming
clear that autophagy and major antioxidant pathways act in concert
to combat the deleterious effects of intracellular redox imbalance
(Dodson et al., 2015). Indeed, the autophagy-lysosomal pathway is
particularly important in protecting endothelial cells against redox
stress-induced proteotoxicity, since it can degrade redox-damaged
proteins without causing aberrant changes to the redox network
needed for metabolism or signaling (Dodson et al., 2015). Moreover,
accumulating evidence demonstrates that the autophagy pathway
and proteins play a major role in a wide array of vascular processes,
including angiogenesis and the paracrine regulation of vasoactive
substances from the endothelium (Nussenzweig et al., 2015), as
well as in balancing the beneﬁcial and detrimental effects of immu-
nity and inﬂammation (Kuballa et al., 2012; Levine et al., 2011),
thereby contributing to protect against both abnormal angiogenic
responses and infectious, autoimmune and inﬂammatory diseases.
Thus, autophagy constitutes also a major candidate mechanism
for mediating the crosstalk between oxidative stress, inﬂamma-
tion and angiogenesis, and integrating consequent cell responses
in health and disease.
In this light, it is also possible to provide an alternative inter-
pretation for recent ﬁndings suggesting that CCM arise from
endothelial gain of MEKK3-KLF2/4 signaling (Cuttano et al., 2016;
Zhou et al., 2016). Indeed, it is possible to envisage a hypothetical
mechanistic model whereby the upregulation of the MEKK3-KLF2/4
signaling occurring upon loss-of-function of CCM proteins could be
part of an abnormal adaptive response consequent to autophagic
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efects and increased ROS levels associated with this loss. Con-
istently, growing evidence suggests that MEKK3, KLF2 and KLF4
lay a major role in endothelial redox homeostasis by acting both
s upstream regulators and downstream targets of redox signal-
ng (Chen et al., 2015; Hamik and Jain, 2012; Irani, 2011; Marin
t al., 2013; Son et al., 2011) and autophagy (Guixe-Muntet et al.,
016; Guo et al., 2013; Liao et al., 2015; Linares et al., 2015).
peciﬁcally, whereas it has been recently reported that crosstalk
etween autophagy and KLF2 determines endothelial cell pheno-
ype and microvascular function (Guixe-Muntet et al., 2016), there
s evidence that KLF4 is a nodal transcriptional regulator of mito-
hondrial homeostasis and clearance via regulation of autophagy
Liao et al., 2015). On the other hand, it is known that the expres-
ion of these cytoprotective transcription factors is modulated by
timuli that induce oxidative stress and inﬂammatory responses
n endothelial cells, such as disturbed ﬂow and oxidized lipids,
nd is tightly regulated by redox-sensitive pathways acting at
ultiple levels, including transcriptional, posttranscriptional, and
osttranslational. In turn, these KLFs regulate other redox-sensitive
athways to ultimately modulate the oxidative and inﬂammatory
tate of the endothelium, suggesting that they are involved in a
omplex and ﬁne-tuned network of redox signaling that coor-
inates cellular responses to oxidative stress and inﬂammatory
timuli (Hamik and Jain, 2012; Irani, 2011; Marin et al., 2013).
hus, it is possibly that the recently reported causative relation-
hip between the hyperexpression of two normally cytoprotective
ranscription factors, such as KLF2 and KLF4, and CCM pathogen-
sis (Cuttano et al., 2016; Zhou et al., 2016) could be connected
o autophagic defects and oxidative stress events associated with
oss-of-function of CCM proteins. Accordingly, growing evidence
uggests that autophagic defects and elevation of intracellular ROS
bove a critical threshold may  lead to the persistent hyperactiva-
ion of transcription factors known to play a crucial role in redox
omeostasis maintenance and cell defense against oxidative stress,
ncluding NRF2 and a member of the KLF family, resulting in an
bnormal cellular stress response that paradoxically reduces oxida-
ive stress resistance leading to disease (Komatsu and Ichimura,
010; Zucker et al., 2014). More in general, consistent with the
ual physiological and pathological activities of redox-sensitive
LFs, it is now well established that in all biological systems,
ncluding vascular tissues, redox reactions bear the Janus faceted
eature of promoting both physiological signaling responses and
athophysiological cues, as well as that endogenous antioxidant
olecules and mechanisms participate in both scenarios (Dodson
t al., 2015; Espinosa-Diez et al., 2015; Holmstrom and Finkel,
014). Indeed, emerging evidence demonstrates that only inter-
ediate levels of major regulators of antioxidant responses are
eneﬁcial, although both the low and high concentration thresh-
lds for physiological vs. pathological effects may  vary largely
epending on genetic and environmental factors, and the cellular
ontext (Dodson et al., 2015). Taken together with these consid-
rations, the alternative interpretation provided above could also
xplain the apparent paradox that both loss (Fisher et al., 2015)
nd gain (Zhou et al., 2016) of MEKK3 function result in similar
ffects, including increased Rho/ROCK activity, impairment of neu-
ovascular integrity, and brain blood vessels leakage, while only
ntermediate levels seem to be beneﬁcial for the homeostasis of
rain vasculature (Zhou et al., 2016).
Future studies are required to pave the way along the novel and
ntricate research avenues traced out by the potential interconnec-
ions among recent ﬁndings, including the emerging evidence that a
ne-tuned crosstalk between redox signaling and autophagy plays pivotal role in modulating both the pleiotropic functions of CCM
roteins and the interplay between oxidative stress, inﬂammation
nd angiogenesis in CCM disease pathogenesis. Nonetheless, the
ovel therapeutic perspectives that recent scientiﬁc discoveries areiochemistry & Cell Biology 81 (2016) 254–270 265
opening up justify the commitment to address these difﬁcult but
exciting new research challenges.
8. Concluding remarks
The scientiﬁc advances and breakthroughs into the phys-
iopathological functions of CCM proteins outlined in this review
bring into view a new mechanistic landscape in which defec-
tive autophagy and altered redox signaling emerge as the major
molecular mechanisms that underlie the pleiotropic effects of CCM
protein dysfunctions, whereas oxidative stress and inﬂammation
loom large as the key pathogenic determinants of CCM disease
onset and progression. Consistently, emerging evidence suggests
that autophagy, oxidative stress and inﬂammation are inextrica-
bly linked, and play major roles in the onset and progression of
other vascular diseases (Choi et al., 2013; Nakahira et al., 2014;
Ryter et al., 2010; Scherz-Shouval and Elazar, 2011; Vindis, 2015).
Furthermore, it is clearly established that oxidative stress and
inﬂammatory events have a focal nature and can indeed occur
locally in the brain vasculature, triggering focal endothelial dys-
function in genetically predisposed blood vessels (Faraci, 2011). To
this regard, it is noteworthy that recent population-based cohort
studies have suggested that CCM disease pathogenesis involves an
intricate interplay between multiple factors, including genetic and
environmental risk factors associated with enhanced susceptibil-
ity to oxidative stress and inﬂammation (Choquet et al., 2014a, b,
2016; Trapani and Retta, 2015). Indeed, besides providing further
support to the important role of oxidative stress and inﬂammation
in the onset and progression of CCM disease, this evidence suggests
also a potential explanation for the heterogeneity described among
affected individuals.
In view of this new mechanistic scenario, it is also possible to
speculate that the loss-of-function of CCM genes may  affect mainly
low-blood-ﬂow capillary beds due to their enhanced susceptibility
to oxidative stress events. Consistently, it is now well understood
that endothelial cells display remarkable heterogeneity in struc-
ture and function (Aird, 2012; Garlanda and Dejana, 1997), and
respond differently to different proﬁles of hemodynamic forces,
including induction of either antioxidant or pro-oxidant responses
by high and low shear stress, respectively (Heo et al., 2011; White
and Frangos, 2007). Indeed, the molecular basis of endothelial cell
heterogeneity and the mechanotransduction mechanisms under-
lying endothelium’s ability to discriminate between ﬂow proﬁles
are beginning to be elucidated (Heo et al., 2011; Li et al., 2005;
Nigro et al., 2011; Nolan et al., 2013). On the other hand, it is
becoming clear that there is a multiplicity of factors inherent to
the physiopathology of NVUs and brain microvascular endothelial
cells that increase opportunities for local oxidative stress events
(Freeman and Keller, 2012). Together these mechanisms may  plau-
sibly explain both the focal nature of CCM lesions and the large
inter-individual variability in CCM disease onset, progression, and
severity. Indeed, the focal nature of CCM lesions has been a con-
sistent observation in both naturally-occurring and experimental
CCM, although the local determinants of focal lesion development
have so far remained elusive or merely justiﬁed by the Knudson’s
genetic two-hit hypothesis. In particular, the possibility that local
oxidative stress and inﬂammation events are indeed the key focal
determinants of lesion development and may  act in concert to drive
CCM pathogenesis can explain the clear discrepancy between the
pan-endothelial loss of CCM proteins and the focal nature of CCM
lesions in neonatal mouse models (Boulday et al., 2011; Chan et al.,
2011). Intriguingly, there is evidence that oxidative stress occurs
after normal birth (Wilhelm et al., 2016), as well as that the imma-
ture brain is particularly susceptible to free radical injury because
of its poorly developed scavenging systems and high availability
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f iron for the catalytic formation of free radicals (Blomgren and
agberg, 2006). Besides providing further support to the role of
xidative stress in CCM pathogenesis, these observations could
lso explain why the formation of CCM-like lesions in neonatal
ouse models of CCM disease occur only if the endothelial-speciﬁc
eletion of CCM genes is induced immediately after birth (P1)
ut not in the adult phase (Boulday et al., 2011). Furthermore,
here is evidence that cerebral endothelial cells contain a rela-
ively high density of mitochondria, which may  in part reﬂect the
igh metabolic demands of maintaining the BBB (Oldendorf et al.,
977), suggesting that mitochondrial dysfunction could have a par-
icularly relevant impact on the brain vasculature. Taken together
ith the ﬁndings that mitochondrial dysfunction, increased ROS
roduction and impairment of autophagy are major hallmarks of
oss-of-function of CCM proteins (Goitre et al., 2010; Marchi et al.,
015), this evidence provides another plausible explanation to the
referential occurrence of CCM lesions in the brain.
Finally, the mechanistic landscape outlined in this review brings
o the forefront distinct therapeutic perspectives, barely dreamt
 decade ago, which now seem legitimately attainable. However,
iven that most of the emerging potential therapeutic compounds
nﬂuence redox-sensitive mechanisms, both their low and high
oncentration thresholds for physiological vs. pathological effects
hould be carefully considered. Indeed, the existence of a physio-
ogical role of speciﬁc ROS concentrations can explain some of the
egative results from clinical trials in which large doses of exoge-
ously administered antioxidants or hyperactivation of antioxidant
athways with electrophilic therapeutics failed to improve out-
omes of vascular diseases or resulted even deleterious (Dodson
t al., 2015; Johansen et al., 2005).
In conclusion, this review highlighted current evidence for a
ajor involvement of oxidative stress and inﬂammation in CCM
isease, arguing that the interplay between these potential deter-
inants should be considered and examined using an integrative
ystemic approach in order to better understand the complexity
f the underlying molecular mechanisms. Such an approach may
rovide novel valuable insights into CCM pathogenesis, facilitating
he development of novel targeted, safe and effective therapeutic
trategies to counteract disease progression and clinical severity,
ncluding drug combination and personalized medicine strategies.
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